Aptorum Group Ltd
APM
Aptorum Group Ltd. is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs. It focuses primarily on oncology, including orphan oncology indications, infectious diseases, metabolic diseases, and women's health, through its Therapeutics segment, which develops drug molecules and diagnostic technologies. Key pipeline candidates include SACT-1, a repurposed drug in phase 1 trials for neuroblastoma and other cancers, and ALS-4, a small molecule in phase 1 for bacterial infections such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also advances preclinical programs like RPIDD for rapid pathogen diagnostics, SACT-COV19 for coronavirus, and others targeting bacterial infections and specific indications. Additionally, Aptorum Group Ltd. operates a Non-Therapeutics segment involving healthcare services and diagnostics. Founded in 2010 and headquartered in the United Kingdom, it plays a role in addressing critical gaps in biopharmaceutical innovation for challenging medical conditions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$1M
▲ +66.9% YoY
Op. Margin
–
ROIC
-8.87%
▲ +5.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -54.4% YoY
Op. Cash Flow (TTM)
-$2M
▼ -54.4% YoY
Net Debt
-$10K
Net Cash Position
Cash & Equiv.
$3M
Continue Research
Peers
Biotechnology · Pick stocks to compare with APM
Aptorum Group (APM) in three numbers
- Quality score
- 20/100
- Best check: share count change, -87.3%. Weakest: return on capital, -8.9%.
- Quality
Questions about Aptorum Group
Is Aptorum Group a high-quality business?
Aptorum Group scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at -87.3%, and its weakest is return on capital at -8.9%. The Quality tab shows every check against its target.
Does Aptorum Group (APM) pay a dividend?
No. Aptorum Group (APM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.